What were Alembic Pharmaceuticals Ltd's latest quarterly results?
Alembic Pharmaceuticals Ltd's latest quarterly results (Mar 2026) show
- PAT Growth YoY: +28.7%
- Revenue Growth YoY: +4.4%
- Operating Margin: 12.0%
Alembic Pharmaceuticals Ltd: Stock Analysis & Fundamentals
Updated this weekAlembic Pharmaceuticals Ltd (Pharma - Formulators) — fundamental analysis, earnings data, and key metrics. PE: 20.8. ROE: 13.4%. This stock is not currently in the Nifty 500 momentum outperformers list.
Alembic Pharmaceuticals Ltd Key Facts
Key Numbers
Current Price
₹772
Dividend Yield
1.43%
Market Cap
15.2K Cr
Valuation
N/AOther Top Pharma - Formulators Stocks Beating Nifty 500
Frequently Asked Questions: Alembic Pharmaceuticals Ltd
Based on publicly available financial data. This is educational research, not investment advice.
What is Alembic Pharmaceuticals Ltd's current PE ratio?
Alembic Pharmaceuticals Ltd's current PE ratio is 20.8x.
- Current PE: 20.8x
- Market Cap: 15.2K Cr
- Dividend Yield: 1.43%
What is Alembic Pharmaceuticals Ltd's price-to-book ratio?
Alembic Pharmaceuticals Ltd's price-to-book ratio is 2.7x.
- Price-to-Book (P/B): 2.7x
- Book Value per Share: ₹289
- Current Price: ₹772
Is Alembic Pharmaceuticals Ltd a fundamentally strong company?
Alembic Pharmaceuticals Ltd's fundamental strength based on key financial ratios
- Return on Capital (ROCE): 13.0%
Is Alembic Pharmaceuticals Ltd debt free?
Alembic Pharmaceuticals Ltd has a debt-to-equity ratio of N/A.
- Total Debt: ₹1,000 Cr
What is Alembic Pharmaceuticals Ltd's return on equity (ROE) and ROCE?
Alembic Pharmaceuticals Ltd's return ratios over recent years
- FY2024: ROCE 13.0%
- FY2025: ROCE 13.0%
- FY2026: ROCE 13.0%
Is Alembic Pharmaceuticals Ltd's cash flow positive?
Alembic Pharmaceuticals Ltd's operating cash flow is positive (FY2026).
- Cash from Operations (CFO): ₹783 Cr
- Free Cash Flow (FCF): ₹277 Cr
- CFO/PAT Ratio: 117% (strong cash conversion)
What is Alembic Pharmaceuticals Ltd's dividend yield?
Alembic Pharmaceuticals Ltd's current dividend yield is 1.43%.
- Dividend Yield: 1.43%
- Current Price: ₹772
Who holds Alembic Pharmaceuticals Ltd shares — promoters, FII, DII?
Alembic Pharmaceuticals Ltd's shareholding pattern (Mar 2026)
- Promoters: 69.7%
- FII (Foreign): 4.3%
- DII (Domestic): 16.2%
- Public: 9.8%
Is promoter holding increasing or decreasing in Alembic Pharmaceuticals Ltd?
Alembic Pharmaceuticals Ltd's promoter holding has remained stable recently.
- Current Promoter Holding: 69.7% (Mar 2026)
- Previous Quarter: 69.7% (Dec 2025)
- Change: 0.00% (stable)
Is Alembic Pharmaceuticals Ltd a new momentum entry or an established outperformer?
Alembic Pharmaceuticals Ltd is an established outperformer with 1 weeks of consecutive Nifty 500 outperformance.
Is Alembic Pharmaceuticals Ltd worth studying for long term investment?
Based on quantitative research signals, here is why Alembic Pharmaceuticals Ltd may be worth studying
- Cash flow is positive — CFO ₹783 Cr
What is the investment thesis for Alembic Pharmaceuticals Ltd?
Alembic Pharmaceuticals Ltd investment thesis summary:
What is the future outlook for Alembic Pharmaceuticals Ltd?
Alembic Pharmaceuticals Ltd's forward outlook based on current data signals
- Insufficient data for a forward assessment — monitoring for more signals
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.